By unfavourable, I do not mean negative. Rather, I think our...

By unfavourable, I do not mean negative. Rather, I think our 'slice of the pie' will not be commensurate with the volume being sold by Ellume (ie SH may be underwhelmed).

DT says "Ellume was the original seed customer in ADO's strategy to demonstrate the value that AnteoBind can bring to assay development..."

My take is that the supply agreement with Ellume was not entered into for the primary objective of revenue, but rather to promote our product to the market (mission accomplished, by the way). That view is reinforced when one searches "seeding", which I gather is the reference to "seed customer" - see https://en.wikipedia.org/wiki/Seeding_trial.

Don't get me wrong, I think the announcement is a massive coup for the validation of our product. I am mindful, however, that revenue may not materially increase until that 2016 agreement is renegotiated (or new buyers come onboard).